Otsuka and Prasco Sign a Commercial Supply Agreement for PLETAL® Tablets

- Prasco will market the first generic of PLETAL® (cilostazol) Tablets under the established name Cilostazol in 50 mg, and 100 mg strengths
- Cilostazol is the latest Prasco Authorized Generic product

Cincinnati, Ohio, October 18, 2004 — Prasco Laboratories, a privately-held pharmaceutical company located in Cincinnati, Ohio, announced today that—under a commercial supply agreement with Otsuka America Pharmaceutical, Inc.—it has initiated shipments of Cilostazol Tablets in the 50 mg and 100 mg strengths. Cilostazol is the authorized generic version of Otsuka’s PLETAL®, which is a PDE-111 inhibitor indicated for the treatment of intermittent claudication (IC). Prasco has received the rights to market 50 mg and 100 mg strength Cilostazol in the United States.

Prasco Authorized Generics
Cilostazol is the latest product from Prasco in its Authorized Generics and Product Lifecycle Extension Program, bringing consumers brand quality, generic priced pharmaceuticals. Cilostazol, manufactured for Prasco under a commercial supply agreement with Otsuka America Pharmaceutical, Inc., is an authorized generic version of Otsuka’s PLETAL.

“We are in the business of marketing Prasco Authorized Generics,” said Prasco Chief Executive Officer E. Thomas Arington. “Our business model was developed to encourage more competition and benefit consumers through significant cost savings on brand quality products”. “We believe that Prasco Authorized Generics will play an even bigger role in the pharmaceutical marketplace of the future because generics will be made available faster with the consistent quality and reliability of supply that comes from innovator companies.

“Prasco serves as a link between brand companies and the generics industry—partnering with companies whose
brand products face current or near-term generic competition. The entire pharmaceutical supply chain benefits
from Prasco Authorized Generics because we supply brand quality products at generic prices.”

Arington concluded “We are especially proud to have established this marketing relationship with Otsuka, a leader in the pharmaceutical industry. We feel that our agreement will be especially beneficial to the consuming public.”

About Prasco
Founded by Arington in 2002, Prasco’s mission is to provide both quality products and significant cost-savings to the consumer. Prasco is a leading multi-source marketing and distribution company that utilizes a versatile, horizontally-integrated business approach to efficiently link manufacturers to retailers to consumers. Prasco combines its intellectual property with the special capabilities of selected partners to realize opportunities and benefit consumers by finding and filling unmet needs within the pharmaceutical marketplace.

Prasco’s goal is to lead the field in bringing to consumers Prasco Authorized Generics, which are brand products sold under the Prasco private label. Prasco’s executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company’s corporate capabilities is its sales/marketing and business development teams. Prasco’s product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.

The company operates from a 54,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems—including DEA-approved facilities for Schedule II-V controlled drug products.

###

CONTACT:
Jeff Zurcher, Advisor to the Chairman, Communications
Prasco Laboratories
513-618-3333
website: www.prasco.com

 

CUSTOMER SERVICE
1.866.525.0688
Monday - Friday
8:30 AM - 5:00 PM EST


Need product information?

SEARCH PRODUCTS